Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.66 |
| ▸ | KDR | P35968 | 9/20 | 0.65 |
| ▸ | FLT1 | P17948 | 5/20 | 0.65 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.65 |
| ▸ | FLT4 | P35916 | 3/20 | 0.65 |
| ▸ | SRC | P12931 | 7/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.60 |
| ▸ | KIT | P10721 | 3/20 | 0.60 |
| ▸ | ERBB3 | P21860 | 3/20 | 0.60 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.60 |
| ▸ | CIT | O14578 | 2/20 | 0.60 |
| ▸ | GAK | O14976 | 2/20 | 0.60 |
| ▸ | EPHB6 | O15197 | 2/20 | 0.60 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.60 |
| ▸ | STK17B | O94768 | 2/20 | 0.60 |
| ▸ | STK10 | O94804 | 2/20 | 0.60 |
| ▸ | ABL1 | P00519 | 2/20 | 0.60 |
| ▸ | LCK | P06239 | 2/20 | 0.60 |
| ▸ | LYN | P07948 | 2/20 | 0.60 |
| ▸ | RET | P07949 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29945003 | 0.87 | EGFR (0.71) | EGFRKDRFLT1FGFR1FLT4 | |
| SCHEMBL23406747 | 0.87 | EGFR (0.71) | EGFRKDRFLT1FGFR1FLT4 | |
| SCHEMBL2963866 | 0.86 | EGFR (0.80) | EGFRKDRFLT1FLT4SRC | |
| SCHEMBL3243872 | 0.86 | EGFR (0.61) | EGFRKDRFLT1FGFR1FLT4 | |
| SCHEMBL3244484 | 0.83 | EGFR (0.80) | EGFRKDRFLT1SRCERBB2 | |
| SCHEMBL29944985 | 0.83 | EGFR (0.65) | EGFRKDRFLT1FGFR1FLT4 | |
| SCHEMBL23406626 | 0.83 | EGFR (0.65) | EGFRKDRFLT1FGFR1FLT4 | |
| SCHEMBL21350019 | 0.83 | EGFR (0.80) | EGFRKDRFLT1FLT4SRC | |
| SCHEMBL7211048 | 0.82 | EGFR (0.78) | EGFRKDRFLT1FGFR1FLT4 | |
| SCHEMBL25371013 | 0.81 | EGFR (0.60) | EGFRKDRFLT1FGFR1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1411993-B1 | RADIOLABELED IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND THEIR USE IN RADIOIMAGING AND RADIOTHERAPY | YISSUM RES DEV CO (IL) | 2010-05-05 | — | — | EP | disclosed |
| EP-1411993-A4 | RADIOLABELED IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND THEIR USE IN RADIOIMAGING AND RADIOTHERAPY | YISSUM RES DEV CO (IL) | 2007-08-01 | — | — | EP | disclosed |
| US-7172749-B2 | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2007-02-06 | — | — | US | disclosed |
| EP-1673110-A2 | RADIOLABELED ANILINOQUINAZOLINES AND THEIR USE IN RADIOIMAGING AND RADIOTHERAPY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005023315-A2 | RADIOLABELED ANILINOQUINAZOLINES AND THEIR USE IN RADIOIMAGING AND RADIOTHERAPY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2005-03-17 | — | — | WO | disclosed |
| US-20040265228-A1 | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2004-12-30 | — | — | US | disclosed |
| EP-1411993-A2 | RADIOLABELED IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND THEIR USE IN RADIOIMAGING AND RADIOTHERAPY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-04-28 | — | — | EP | disclosed |
| WO-2002073235-A2 | RADIOLABELED IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND THEIR USE IN RADIOIMAGING AND RADIOTHERAPY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040265228-A1 | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy | EGFR, ERBB2, TK1 | EGFR 1/4885KDR 16/4885FLT1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.